Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion type Assertion NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_head.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion evidence source_evidence_literature NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion SIO_000772 23847380 NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion wasDerivedFrom befree-2016 NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.
- NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_assertion wasGeneratedBy ECO_0000203 NP1093335.RAAD0py36Csk2fE-tobS6Wc1lRYFIscnHSzdiaQb9h35o130_provenance.